The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple sclerosis

Journal of Neuroimmunology

Volumn 264, Issue 1-2, 2013, Pages 100-105

  Axelsson, Markus ^a   Mattsson, Niklas ^a,b   Malmeström, Clas ^a   Zetterberg, Henrik ^a   Lycke, Jan ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

B cell; CXCL13; Intrathecal IgG; Mitoxantrone; Multiple sclerosis; Oligoclonal band (OCB)

Indexed keywords

ALBUMIN; CXCL13 CHEMOKINE; IMMUNOGLOBULIN G; MITOXANTRONE; OLIGOCLONAL BAND;

ADULT; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; IMMUNOGLOBULIN PRODUCTION; IMMUNOSUPPRESSIVE TREATMENT; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL;

B-CELL; CXCL13; INTRATHECAL IGG; MITOXANTRONE; MULTIPLE SCLEROSIS; OLIGOCLONAL BAND (OCB);

ADOLESCENT; ADULT; CHEMOKINE CXCL13; DISABILITY EVALUATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOSUPPRESSION; INJECTIONS, SPINAL; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MITOXANTRONE; MULTIPLE SCLEROSIS; OLIGOCLONAL BANDS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84886774011     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2013.09.003     Document Type: Article

References (49)

1. Andersson M., Alvarez-Cermeno J., Bernardi G., Cogato I., Fredman P., Frederiksen J., Fredrikson S., Gallo P., Grimaldi L.M., Gronning M., et al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J. Neurol. Neurosurg. Psychiatry 1994, 57:897-902.
2. Axelsson M., Malmestrom C., Nilsson S., Haghighi S., Rosengren L., Lycke J. Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis. J. Neurol. 2011, 258:882-888.
3. Blennow K., Wallin A., Fredman P., Gottfries C.G., Karlsson I., Svennerholm L. Intrathecal synthesis of immunoglobulins in patients with Alzheimer's disease. Eur. Neuropsychopharmacol. 1990, 1:79-81.
4. Blennow K., Fredman P., Wallin A., Gottfries C.G., Skoog I., Wikkelso C., Svennerholm L. Protein analysis in cerebrospinal fluid. III. Relation to blood-cerebrospinal fluid barrier function for formulas for quantitative determination of intrathecal IgG production. Eur. Neurol. 1993, 33:134-142.
5. Bloom B.R. Immunological changes in multiple sclerosis. Nature 1980, 287:275-276.
6. Calabrese M., Federle L., Bernardi V., Rinaldi F., Favaretto A., Varagnolo M.C., Perini P., Plebani M., Gallo P. The association of intrathecal immunoglobulin synthesis and cortical lesions predicts disease activity in clinically isolated syndrome and early relapsing-remitting multiple sclerosis. Mult. Scler. 2011, 18:174-180.
7. Cameron E.M., Spencer S., Lazarini J., Harp C.T., Ward E.S., Burgoon M., Owens G.P., Racke M.K., Bennett J.L., Frohman E.M., Monson N.L. Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis. J. Neuroimmunol. 2009, 213:123-130.
8. Cepok S., Rosche B., Grummel V., Vogel F., Zhou D., Sayn J., Sommer N., Hartung H.P., Hemmer B. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain 2005, 128:1667-1676.
9. Correale J., De Los Milagros Bassani Molinas M. Oligoclonal bands and antibody responses in multiple sclerosis. J. Neurol. 2002, 249:375-389.
10. Delmotte P., Gonsette R. Biochemical findings in multiple sclerosis IV. Isoelectric focusing of the CSF gamma globulins in multiple sclerosis (262 cases) and other neurological diseases (272 cases). J. Neurol. 1977, 215:27-37.
11. Fassas A., Passweg J.R., Anagnostopoulos A., Kazis A., Kozak T., Havrdova E., Carreras E., Graus F., Kashyap A., Openshaw H., Schipperus M., Deconinck E., Mancardi G., Marmont A., Hansz J., Rabusin M., Zuazu Nagore F.J., Besalduch J., Dentamaro T., Fouillard L., Hertenstein B., La Nasa G., Musso M., Papineschi F., Rowe J.M., Saccardi R., Steck A., Kappos L., Gratwohl A., Tyndall A., Samijn J. Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. J. Neurol. 2002, 249:1088-1097.
12. Freedman M.S., Thompson E.J., Deisenhammer F., Giovannoni G., Grimsley G., Keir G., Ohman S., Racke M.K., Sharief M., Sindic C.J., Sellebjerg F., Tourtellotte W.W. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch. Neurol. 2005, 62:865-870.
13. Harrer A., Tumani H., Niendorf S., Lauda F., Geis C., Weishaupt A., Kleinschnitz C., Rauer S., Kuhle J., Stangel M., Weber F., Uhr M., Linnebank M., Wildemann B., Jarius S., Guger M., Ayzenberg I., Chan A., Zettl U., Wiendl H., Pilz G., Hitzl W., Weber J., Kraus J. Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy. Mult. Scler. 2002, 19(9):1209-1212.
14. Kabat E.A., Moore D.H., Landow H. An electrophoretic study of the protein components in cerebrospinal fluid and their relationship to the serum proteins. J. Clin. Invest. 1942, 21:571-577.
15. Keir G., Luxton R.W., Thompson E.J. Isoelectric focusing of cerebrospinal fluid immunoglobulin G: an annotated update. Ann. Clin. Biochem. 1990, 27(Pt 5):436-443.
16. Keshgegian A.A., Coblentz J., Lisak R.P. (University of Pennsylvania Case Conference): oligoclonal immunoglobulins in cerebrospinal fluid in multiple sclerosis. Clin. Chem. 1980, 26:1340-1345.
17. Khademi M., Kockum I., Andersson M.L., Iacobaeus E., Brundin L., Sellebjerg F., Hillert J., Piehl F., Olsson T. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult. Scler. 2010, 17:335-343.
18. Kostulas V.K., Link H., Lefvert A.K. Oligoclonal IgG bands in cerebrospinal fluid. Principles for demonstration and interpretation based on findings in 1114 neurological patients. Arch. Neurol. 1987, 44:1041-1044.
19. Kowarik M.C., Pellkofer H.L., Cepok S., Korn T., Kumpfel T., Buck D., Hohlfeld R., Berthele A., Hemmer B. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS. Neurology 2011, 76:1214-1221.
20. Krapf H., Morrissey S.P., Zenker O., Zwingers T., Gonsette R., Hartung H.P. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial. Neurology 2005, 65:690-695.
21. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983, 33:1444-1452.
22. Ligocki A.J., Lovato L., Xiang D., Guidry P., Scheuermann R.H., Willis S.N., Almendinger S., Racke M.K., Frohman E.M., Hafler D.A., O'Connor K.C., Monson N.L. A unique antibody gene signature is prevalent in the central nervous system of patients with multiple sclerosis. J Neuroimmunol 2010, (226):192-193.
23. LINK H. Immunoglobulin G and low molecular weight proteins in human cerebrospinal fluid. Chemical and immunological characterisation with special reference to multiple sclerosis. Acta Neurol. Scand. 1967, 43(Suppl. 28):1-136.
24. Link H., Huang Y.M. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. J. Neuroimmunol. 2006, 180:17-28.
25. Lourenco P., Shirani A., Saeedi J., Oger J., Schreiber W.E., Tremlett H. Oligoclonal bands and cerebrospinal fluid markers in multiple sclerosis: associations with disease course and progression. Mult. Scler. 2013, 19(5):577-584.
26. Lublin F.D., Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996, 46:907-911.
27. Malmestrom C., Haghighi S., Rosengren L., Andersen O., Lycke J. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology 2003, 61:1720-1725.
28. Mancardi G.L., Saccardi R., Filippi M., Gualandi F., Murialdo A., Inglese M., Marrosu M.G., Meucci G., Massacesi L., Lugaresi A., Pagliai F., Sormani M.P., Sardanelli F., Marmont A. Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. Neurology 2001, 57:62-68.
29. Mattson D.H., Roos R.P., Arnason B.G. Isoelectric focusing of IgG eluted from multiple sclerosis and subacute sclerosing panencephalitis brains. Nature 1980, 287:335-337.
30. Mattson D.H., Roos R.P., Arnason B.G. Comparison of agar gel electrophoresis and isoelectric focusing in multiple sclerosis and subacute sclerosing panencephalitis. Ann. Neurol. 1981, 9:34-41.
31. Mcdonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., Mcfarland H.F., Paty D.W., Polman C.H., Reingold S.C., Sandberg-Wollheim M., Sibley W., Thompson A., Van Den Noort S., Weinshenker B.Y., Wolinsky J.S. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann. Neurol. 2001, 50:121-127.
32. Meinl E., Krumbholz M., Hohlfeld R. B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation. Ann. Neurol. 2006, 59:880-892.
33. Norrby Humoral Immunity in Neurological Diseases 1979, 289-297. Plenum Press, New York.
34. Olsson J.E., Link H. Immunoglobulin abnormalities in multiple sclerosis. Relation to clinical parameters: exacerbations and remissions. Arch. Neurol. 1973, 28:392-399.
35. Olsson J.E., Nilsson K. Gamma globulins of CSF and serum in multiple sclerosis: isoelectric focusing on polyacrylamide gel and agar gel electrophoresis. Neurology 1979, 29:1381-1391.
36. Olsson T., Kostulas V., Link H. Improved detection of oligoclonal IgG in cerebrospinal fluid by isoelectric focusing in agarose, double-antibody peroxidase labeling, and avidin-biotin amplification. Clin. Chem. 1984, 30:1246-1249.
37. Piccio L., Naismith R.T., Trinkaus K., Klein R.S., Parks B.J., Lyons J.A., Cross A.H. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch. Neurol. 2010, 67:707-714.
38. Polman C.H., Reingold S.C., Banwell B., Clanet M., Cohen J.A., Filippi M., Fujihara K., Havrdova E., Hutchinson M., Kappos L., Lublin F.D., Montalban X., O'connor P., Sandberg-Wollheim M., Thompson A.J., Waubant E., Weinshenker B., Wolinsky J.S. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 2011, 69:292-302.
39. Poser C.M., Paty D.W., Scheinberg L., Mcdonald W.I., Davis F.A., Ebers G.C., Johnson K.P., Sibley W.A., Silberberg D.H., Tourtellotte W.W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 1983, 13:227-231.
40. Rolak L.A., Beck R.W., Paty D.W., Tourtellotte W.W., Whitaker J.N., Rudick R.A. Cerebrospinal fluid in acute optic neuritis: experience of the optic neuritis treatment trial. Neurology 1996, 46:368-372.
41. Roxburgh R.H., Seaman S.R., Masterman T., Hensiek A.E., Sawcer S.J., Vukusic S., Achiti I., Confavreux C., Coustans M., Le Page E., Edan G., Mcdonnell G.V., Hawkins S., Trojano M., Liguori M., Cocco E., Marrosu M.G., Tesser F., Leone M.A., Weber A., Zipp F., Miterski B., Epplen J.T., Oturai A., Sorensen P.S., Celius E.G., Lara N.T., Montalban X., Villoslada P., Silva A.M., Marta M., Leite I., Dubois B., Rubio J., Butzkueven H., Kilpatrick T., Mycko M.P., Selmaj K.W., Rio M.E., Sa M., Salemi G., Savettieri G., Hillert J., Compston D.A. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005, 64:1144-1151.
42. Rudick R.A., Cookfair D.L., Simonian N.A., Ransohoff R.M., Richert J.R., Jacobs L.D., Herndon R.M., Salazar A.M., Fischer J.S., Granger C.V., Goodkin D.E., Simon J.H., Bartoszak D.M., Bourdette D.N., Braiman J., Brownscheidle C.M., Coats M.E., Cohan S.L., Dougherty D.S., Kinkel R.P., Mass M.K., Munchsauer F.E., O'reilly K., Priore R.L., Whitham R.H., et al. Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research group. J. Neuroimmunol. 1999, 93:8-14.
43. Sellebjerg F., Bornsen L., Khademi M., Krakauer M., Olsson T., Frederiksen J.L., Sorensen P.S. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology 2009, 73:2003-2010.
44. Teunissen C.E., Petzold A., Bennett J.L., Berven F.S., Brundin L., Comabella M., Franciotta D., Frederiksen J.L., Fleming J.O., Furlan R., Hintzen R.Q., Hughes S.G., Johnson M.H., Krasulova E., Kuhle J., Magnone M.C., Rajda C., Rejdak K., Schmidt H.K., Van Pesch V., Waubant E., Wolf C., Giovannoni G., Hemmer B., Tumani H., Deisenhammer F. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 2009, 73:1914-1922.
45. Thompson E.J., Kaufmann P., Rudge P. Sequential changes in oligoclonal patterns during the course of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 1983, 46:547-550.
46. Tibbling G., Link H., Ohman S. Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand. J. Clin. Lab. Invest. 1977, 37:385-390.
47. Vandvik B. Oligoclonal IgG and free light chains in the cerebrospinal fluid of patients with multiple sclerosis and infectious diseases of the central nervous system. Scand. J. Immunol. 1977, 6:913-922.
48. Von Glehn F., Farias A.S., De Oliveira A.C., Damasceno A., Longhini A.L., Oliveira E.C., Damasceno B.P., Santos L.M., Brandao C.O. Disappearance of cerebrospinal fluid oligoclonal bands after natalizumab treatment of multiple sclerosis patients. Mult. Scler. 2011, 18:1038-1041.
49. Winges K.M., Gilden D.H., Bennett J.L., Yu X., Ritchie A.M., Owens G.P. Analysis of multiple sclerosis cerebrospinal fluid reveals a continuum of clonally related antibody-secreting cells that are predominantly plasma blasts. J. Neuroimmunol. 2007, 192:226-234.